Danske Bank’s Impact BioMedical IBO Stock Holding History

Danske Bank’s Portfolio IBO Stock Details IBO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$22	Buy	+4	New	+$23	﹤0.01%	1038
2026 Q2	–	Hold	0	–	–	–	1152
2026 Q1	–	Hold	0	–	–	–	1151
2025 Q4	–	Hold	0	–	–	–	1543
2025 Q3	–	Hold	0	–	–	–	1475
2025 Q2	–	Hold	0	–	–	–	1504
2025 Q1	–	Hold	0	–	–	–	1338
2024 Q4	–	Hold	0	–	–	–	1363
2024 Q3	–	Hold	0	–	–	–	1551

Other funds holding IBO

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Global Trust Asset Management West Palm Beach, Florida $321M AUM 60.77% 1-Year Est. Return

Newbridge Financial Services Group Boca Raton, Florida $868M AUM 42.47% 1-Year Est. Return

Burk Holdings Tulsa, Oklahoma $289M AUM 16.51% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Danske Bank's IBO Position: Q3 2026 in Review

Danske Bank opened a new position in Impact BioMedical (IBO) in Q3 2026: 4 shares worth $22. The stake represents ﹤0.01% of the portfolio and ranks #1038 among its holdings.

6 funds tracked by Wall St. Rank hold IBO as of Q3 2026.

Danske Bank held 4 shares of Impact BioMedical worth $22 as of Q3 2026.
Impact BioMedical was a new Danske Bank position in Q3 2026.
Impact BioMedical made up ﹤0.01% of Danske Bank's portfolio in Q3 2026, its #1038 holding.
6 funds tracked by Wall St. Rank held Impact BioMedical as of Q3 2026.

Based on Danske Bank's 13F filing for Q3 2026, filed 9 Nov 2026.